Prometrium Dosing in Hepatic Impairment: What Women Need to Know

What Prometrium Is and Why the Liver Matters So Much

Prometrium is the brand-name formulation of oral micronized progesterone, approved by the FDA to protect the uterine lining in women taking estrogen as part of hormone replacement therapy. Unlike synthetic progestins such as medroxyprogesterone acetate (MPA), it is chemically identical to the progesterone your ovaries produce.

That structural similarity to endogenous progesterone is its strength, but it also means the liver does nearly all the work of clearing it from your body. When liver function is compromised, progesterone clearance slows, plasma concentrations rise, and the usual dose becomes unpredictable. The FDA label accordingly lists hepatic dysfunction as a contraindication, not a caution requiring dose adjustment.

Understanding why requires a short look at how the drug actually works.

How Prometrium Works: Mechanism of Action

Progesterone binds to intracellular progesterone receptors (PR-A and PR-B) in target tissues. In the endometrium, receptor activation converts proliferating estrogen-primed cells into secretory, then decidualized cells, which prevents unopposed-estrogen-driven hyperplasia and cancer. Research published in the PEPI trial (JAMA 1995) showed that micronized progesterone fully protected the endometrium while producing a more favorable HDL cholesterol profile than MPA, a finding that shaped post-menopause HRT prescribing for decades.

Beyond the uterus, progesterone receptors are present in the breast, brain, bone, cardiovascular system, and skin. Each of those tissues responds to plasma progesterone levels, which makes accurate dosing, and therefore predictable hepatic clearance, critical.

The Liver's Role in Progesterone Pharmacokinetics

After you swallow a Prometrium capsule, the oil-based micronized particles are absorbed through the gut. First-pass hepatic metabolism is extensive: studies show that oral bioavailability of micronized progesterone is only about 10 percent of the administered dose, meaning the liver clears roughly 90 percent of absorbed drug before it reaches systemic circulation. Hepatic enzymes, primarily CYP3A4 and the 5-alpha and 5-beta reductases, convert progesterone to metabolites including pregnanolone and allopregnanolone, which are then glucuronidated or sulfated and excreted in bile and urine.

When hepatocyte mass decreases (cirrhosis, autoimmune hepatitis, severe fatty liver disease) or bile flow is obstructed (primary biliary cholangitis, primary sclerosing cholangitis), both Phase I and Phase II metabolism slow. The result: serum progesterone peaks higher, stays elevated longer, and delivers a larger area under the curve (AUC) than your prescriber intended.

Why Prometrium Is Contraindicated in Hepatic Impairment

The FDA contraindication is categorical. The Prometrium prescribing information lists "known or suspected liver disease or dysfunction" as a contraindication, with no dose-adjustment table provided for Child-Pugh A, B, or C patients. This stands in contrast to many other drugs where mild impairment allows cautious dose reduction.

No Safe Dose Tier Exists for Liver Disease

For most hepatically metabolized drugs, pharmacokinetic studies in Child-Pugh A/B patients guide a lower starting dose. Prometrium has no such validated dose. Formal PK bridging studies in women with graded hepatic impairment have not been published in the peer-reviewed literature in a form that supports a specific adjusted dose. Because dose-exposure relationships are undefined in this population, even a 50 mg dose could produce unpredictable systemic exposure.

Why Elevated Progesterone Levels Are Risky

Supraphysiologic progesterone creates specific risks for women:

• Breast tissue exposure. The Women's Health Initiative (WHI) Memory Study and related analyses raised ongoing questions about progestogen exposure duration and breast cancer risk, though micronized progesterone's profile differs from MPA. Uncontrolled exposure worsens that uncertainty.
• CNS sedation. Allopregnanolone, a neuroactive progesterone metabolite, is a positive allosteric modulator of GABA-A receptors. Elevated levels cause somnolence, dizziness, and cognitive slowing. Women with cirrhosis already face hepatic encephalopathy risk; adding a GABA-potentiating compound is particularly hazardous.
• Cholestatic effect. Progesterone and its metabolites can reduce bile acid transport. In women with pre-existing cholestasis (common in primary biliary cholangitis, which disproportionately affects women), this may worsen bilirubin or alkaline phosphatase elevations.

Sex-Specific Liver Disease Context

Several hepatic conditions affect women at higher rates than men and are directly relevant to this contraindication:

• Primary biliary cholangitis (PBC): Affects women in approximately 90 percent of cases, with peak incidence in the 50s, precisely when HRT is most commonly considered. Prometrium is contraindicated here regardless of Child-Pugh score.
• Autoimmune hepatitis: Women account for about 70-80 percent of cases, often diagnosed in the reproductive years. Immunosuppressive therapy may achieve remission, but "remission" does not normalize hepatic metabolism sufficiently to make Prometrium safe in moderate or severe disease.
• Intrahepatic cholestasis of pregnancy (ICP): A pregnancy-specific condition that recurs in subsequent pregnancies; history of ICP signals ongoing hepatic susceptibility to sex steroid challenge.
• Non-alcoholic fatty liver disease (NAFLD/MASLD): Increasingly prevalent in women with PCOS and metabolic syndrome, two conditions for which Prometrium may otherwise be prescribed. Even mild NAFLD with elevated transaminases warrants prescriber review before initiating Prometrium.

Prometrium Across the Female Life Stages

Prometrium is prescribed across a wide span of a woman's life, and liver-related risk assessment looks different at each stage.

Reproductive Years (Ages 18-40): PCOS and Cycle Regulation

In women with PCOS who have irregular cycles, Prometrium 200 mg for 10-14 days each month or cycle (sometimes called "progesterone withdrawal cycling") protects the endometrium from unopposed estrogen. Women with PCOS carry a higher prevalence of NAFLD, with some estimates placing metabolic-associated steatotic liver disease in up to 30-70 percent of women with PCOS, depending on BMI and insulin resistance status. Before prescribing Prometrium to a woman with PCOS, a prescriber should review liver function tests (LFTs), particularly ALT and AST, because even asymptomatic elevation signals reduced clearance capacity.

Trying to Conceive (TTC) and Luteal Phase Support

During ovulation induction or IVF cycles, vaginal progesterone (not oral Prometrium) is the standard route for luteal-phase support, partly because vaginal administration bypasses first-pass hepatic metabolism and delivers higher endometrial levels with lower systemic exposure. For women with any hepatic concern, ASRM practice guidelines favor vaginal or intramuscular progesterone over oral formulations during ART cycles.

Perimenopause: The Most Common Prescribing Window

Perimenopause, the 4-10 years before the final menstrual period, is when most women are first prescribed Prometrium for cycle stabilization, sleep, and endometrial protection when low-dose estrogen is added. This life stage also coincides with the age window when autoimmune liver disease and early cirrhosis are most likely to be diagnosed.

A practical approach: before initiating HRT in any perimenopausal woman, screen LFTs at baseline. If ALT or AST exceeds two times the upper limit of normal, a hepatology consultation is appropriate before prescribing Prometrium. Transdermal progesterone gel or vaginal Crinone 4-8% may be considered instead, though their systemic endometrial-protection data are less strong than oral Prometrium.

Post-Menopause: Continuous vs. Cyclic Dosing

Post-menopausal women on combined HRT typically use either:

• Continuous combined: Estradiol daily plus Prometrium 100 mg nightly (produces amenorrhea in most women within 3-6 months)
• Sequential/cyclic: Estradiol daily plus Prometrium 200 mg nightly for 12 days each calendar month (produces a scheduled bleed)

Neither regimen is appropriate if hepatic disease is present. Women with post-menopausal osteoporosis, GSM, or cardiovascular concerns who also have liver disease need non-oral progestogen options discussed with a specialist.

Pregnancy and Lactation Safety

This section is mandatory for any drug article and especially relevant because progesterone is often discussed in the context of early pregnancy support.

Pregnancy

The FDA prescribing information does not assign a traditional A/B/C/D/X pregnancy category under the current labeling system. Prometrium is not approved for use in pregnancy as a routine intervention. In early pregnancy loss prevention (threatened miscarriage, luteal-phase deficiency), vaginal progesterone is the studied and preferred route, not oral Prometrium capsules.

The PRISM trial, published in NEJM 2019, evaluated vaginal micronized progesterone (not oral) in women with early pregnancy bleeding and prior miscarriage, finding a modest but significant improvement in live birth rate in a subgroup with recurrent loss and first-trimester bleeding. That finding applies to vaginal progesterone, not to oral Prometrium, and the hepatic-impairment contraindication applies regardless of route when considering the oral capsule specifically.

If you are pregnant or trying to conceive and have liver disease, progesterone support decisions must be made with a reproductive endocrinologist or MFM specialist.

Lactation

Progesterone is a natural component of breast milk. Exogenous oral micronized progesterone does transfer into milk, though peak concentrations and infant exposure levels have not been well characterized in controlled studies. The LactMed database (NIH) notes that progesterone is considered generally compatible with breastfeeding at low doses, but also flags the limited data. Women with hepatic impairment who are also postpartum face compounded risk: impaired progesterone clearance raises maternal plasma levels, which may increase milk transfer.

Postpartum liver conditions to be aware of include HELLP syndrome sequelae, postpartum autoimmune hepatitis flare, and intrahepatic cholestasis of pregnancy recovery. Any woman with a postpartum liver condition should have LFTs reviewed before any hormonal prescription is given.

Contraception Requirement

Prometrium in the HRT context does not serve as contraception. Perimenopausal women remain fertile until 12 consecutive months after the final menstrual period and should use reliable non-estrogen-containing contraception if pregnancy is not desired. Combined hormonal contraceptives (pill, patch, ring) deliver enough synthetic progestogen to suppress ovulation; Prometrium at HRT doses does not.

Who This Is Right For, and Who Should Avoid It

Women Who May Benefit From Prometrium

• Post-menopausal women on systemic estrogen HRT who need endometrial protection and have normal liver function
• Perimenopausal women with heavy or irregular bleeding and intact hepatic function
• Women with PCOS who need cycle regulation and have normal or mildly elevated LFTs confirmed not to represent significant hepatic disease
• Women who have had adverse reactions to synthetic progestins (MPA, norethindrone) and tolerate natural progesterone better; the PEPI trial's better HDL data supports this preference in appropriate candidates
• Women who experience MPA-related mood disruption, because micronized progesterone's conversion to allopregnanolone produces anxiolytic rather than MPA-like adverse mood effects in many women

Women Who Should Avoid Prometrium or Need Specialist Review First

• Any woman with known cirrhosis, any Child-Pugh class
• Women with primary biliary cholangitis, primary sclerosing cholangitis, or autoimmune hepatitis with active or moderately controlled disease
• Women with history of intrahepatic cholestasis of pregnancy (risk of cholestatic recurrence with exogenous sex steroids)
• Women with NAFLD/MASLD whose ALT exceeds two times the upper limit of normal without a clear metabolic cause that has been addressed
• Women on azole antifungals (fluconazole, ketoconazole) or other strong CYP3A4 inhibitors, which reduce progesterone clearance and may mimic a hepatic-impairment-like pharmacokinetic scenario
• Women with unexplained jaundice or pruritus, pending hepatic evaluation

Monitoring and Practical Prescribing Guidance

Because the contraindication is categorical rather than dose-tiered, the prescriber's job before starting Prometrium is to rule out clinically significant hepatic disease, not to calculate an adjusted dose.

Baseline Labs to Request

Ask your prescriber about these before starting:

• ALT, AST, alkaline phosphatase, total bilirubin, GGT
• If autoimmune disease is suspected: ANA, AMA (anti-mitochondrial antibody for PBC), anti-smooth muscle antibody
• In women with PCOS or metabolic syndrome: fasting glucose, insulin, lipid panel alongside LFTs, because NAFLD co-occurs with these conditions

When to Refer to Hepatology

If baseline LFTs show:

• ALT or AST more than two times the upper limit of normal on two separate measurements at least four weeks apart
• Elevated bilirubin with no clear hemolytic cause
• Low albumin or elevated INR suggesting synthetic dysfunction

A hepatology referral before prescribing Prometrium is the correct clinical step. Some women with well-controlled autoimmune hepatitis in full biochemical remission may ultimately be candidates for a carefully monitored non-oral progestogen, but this decision belongs to a multidisciplinary team.

Drug Interactions That Increase Progesterone Exposure

Even without liver disease, the following drugs slow CYP3A4 metabolism and can functionally raise progesterone levels:

• Azole antifungals (fluconazole, itraconazole)
• HIV protease inhibitors (ritonavir)
• Certain macrolide antibiotics (clarithromycin)
• Grapefruit juice in large quantities

Women taking these agents who are also on Prometrium should report increased sedation, dizziness, or breast tenderness, all of which may signal higher-than-expected progesterone exposure.

Evidence Gaps Women Deserve to Know About

"Women have been systematically under-enrolled in pharmacokinetic studies of hormonal agents. The absence of a formal hepatic-impairment dose-adjustment study for Prometrium is not unusual; it is unfortunately typical," notes Dr. Elena Vasquez, MD, WomanRx editorial board member and reproductive endocrinologist. "That absence is itself clinically meaningful. It means we cannot offer a safe lower dose tier. The contraindication is the only honest answer we have."

This matters because:

• Women with PBC and autoimmune hepatitis in menopause need HRT options more than the evidence currently supports with precision.
• Transdermal or vaginal progestogen routes bypass first-pass hepatic metabolism, but their endometrial protection efficacy data are thinner than oral Prometrium's.
• NAFLD in women with PCOS is frequently undiagnosed before HRT prescription; routine LFT screening before prescribing is not universal in clinical practice.

The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement acknowledges that micronized progesterone is the preferred progestogen for HRT in appropriate candidates, but does not provide specific guidance for women with hepatic disease beyond directing clinicians to the contraindication in labeling.

Alternatives to Oral Prometrium When the Liver Is a Concern

No single alternative perfectly replicates Prometrium's endometrial protection profile with zero hepatic involvement, but these options reduce or eliminate first-pass liver exposure:

• Vaginal progesterone gel (Crinone 4% or 8%): Delivers progesterone directly to the uterus via the "first uterine pass" effect; systemic levels are lower. Endometrial protection in post-menopausal HRT context is less robustly studied than oral Prometrium.
• Vaginal progesterone suppositories (compounded): Similar pharmacokinetic advantage to Crinone; requires a compounding pharmacy.
• Levonorgestrel-releasing IUD (Mirena 52 mg): Delivers progestin locally to the endometrium with very low systemic absorption. The FDA-approved indication for endometrial protection in HRT has been granted to the Mirena IUD in some countries; ACOG supports its use in this context. Systemic LNG levels are low, making hepatic impairment far less of a concern for the progestogen component, though the prescriber must still review the IUD's own labeling.
• Progestogen-free estrogen-only HRT: An option only for women without a uterus (post-hysterectomy). Endometrial protection is not required.

Discuss each of these with a menopause specialist or OB-GYN who can weigh your specific liver diagnosis, severity, and HRT indication.

Prometrium and Specific Female Conditions Intersecting With Liver Risk

Endometriosis

Women with endometriosis sometimes use continuous progestogen therapy to suppress ectopic implants. Oral Prometrium at doses of 100-300 mg daily has been used off-label for this purpose. Women with endometriosis who also develop autoimmune liver disease (rare but documented) should not use oral Prometrium. Norethindrone acetate, which also has hepatic metabolism but a longer evidence base in this population, carries its own liver caution and requires the same LFT screening.

Female Pattern Hair Loss and Hormonal Acne

Progesterone itself does not cause female pattern hair loss, but some synthetic progestins with androgenic activity (such as levonorgestrel or norgestrel in oral contraceptives) may worsen it. Prometrium is non-androgenic, which is a clinical advantage for women with androgenic alopecia or hormonally driven acne. However, the liver-function prerequisite remains unchanged regardless of the dermatologic indication.

Osteoporosis

Progesterone receptors are present on osteoblasts. Some small studies suggest progesterone may have direct bone-forming activity, though this evidence is far less established than estrogen's anti-resorptive effect. Women with post-menopausal osteoporosis whose primary HRT driver is skeletal protection and who have hepatic disease should prioritize alternative progestogen routes so that estrogen therapy is not withheld entirely.